The Fort Worth Press - Protagonist Therapeutics Reports Granting of Inducement Awards

USD -
AED 3.672502
AFN 63.999675
ALL 82.464942
AMD 358.505756
ANG 1.790403
AOA 917.510995
ARS 1549.890095
AUD 1.484825
AWG 1.8025
AZN 1.69797
BAM 1.779156
BBD 2.017129
BDT 124.690139
BGN 1.77347
BHD 0.378157
BIF 3007.43672
BMD 1
BND 1.291033
BOB 11.682086
BRL 5.779027
BSD 1.001496
BTN 94.002656
BWP 14.018585
BYN 3.009424
BYR 19600
BZD 2.014218
CAD 1.429435
CDF 2317.999891
CHF 0.83897
CLF 0.025357
CLP 997.979888
CNY 6.66455
CNH 6.665825
COP 3317.23
CRC 446.292118
CUC 1
CUP 24.035623
CVE 100.306108
CZK 22.186203
DJF 178.348063
DKK 6.795935
DOP 60.867113
DZD 137.037458
EGP 53.662197
ERN 15
ETB 164.376481
EUR 0.90915
FJD 2.296803
FKP 0.758367
GBP 0.758115
GEL 2.594964
GGP 0.758367
GHS 11.732118
GIP 0.758367
GMD 73.502857
GNF 8873.120921
GTQ 7.654066
GYD 209.544342
HKD 7.846115
HNL 26.932961
HRK 6.831965
HTG 131.250142
HUF 331.546502
IDR 18244.45
ILS 3.24895
IMP 0.758367
INR 93.405104
IQD 1518.259596
IRR 1925253.999473
ISK 124.35966
JEP 0.758367
JMD 158.794125
JOD 0.708992
JPY 159.022498
KES 130.110117
KGS 87.449399
KHR 4106.5296
KMF 447.499173
KPW 900.00035
KRW 1336.755015
KWD 0.31145
KYD 0.834633
KZT 445.59873
LAK 22549.202436
LBP 89683.974965
LKR 333.298462
LRD 170.2507
LSL 16.970744
LTL 2.95274
LVL 0.60489
LYD 6.470746
MAD 9.982716
MDL 18.317444
MGA 4555.8128
MKD 55.929347
MMK 2099.8229
MNT 3605.49036
MOP 8.0932
MRU 40.667528
MUR 47.859706
MVR 15.410094
MWK 1736.583325
MXN 18.495385
MYR 4.092502
MZN 63.910547
NAD 16.970667
NGN 1345.960111
NIO 36.851561
NOK 9.65092
NPR 150.403886
NZD 1.81806
OMR 0.384507
PAB 1.001465
PEN 3.415402
PGK 4.572229
PHP 63.696003
PKR 276.920096
PLN 4.00304
PYG 6215.118421
QAR 3.660925
RON 4.861402
RSD 106.933007
RUB 82.456407
RWF 1479.507134
SAR 3.763042
SBD 8.098361
SCR 13.836741
SDG 601.49917
SEK 10.091803
SGD 1.288155
SHP 0.758581
SLE 23.050189
SLL 20969.503664
SOS 572.372042
SRD 37.453497
STD 20697.981008
STN 22.288025
SVC 8.762969
SYP 13002.000337
SZL 16.966036
THB 33.795502
TJS 9.228432
TMT 3.51
TND 3.027513
TOP 2.40776
TRY 50.417725
TTD 6.801694
TWD 32.904501
TZS 2648.102992
UAH 45.525197
UGX 4156.319079
UYU 40.6615
UZS 12027.818082
VES 914.603598
VND 25741
VUV 120.845902
WST 2.802705
XAF 596.363137
XAG 0.021086
XAU 0.000258519845
XCD 2.70255
XCG 1.8049
XDR 0.707052
XOF 596.363137
XPF 108.488699
YER 236.510374
ZAR 16.92753
ZMK 9001.19816
ZMW 20.506056
ZWL 321.999592
SSP 5946.953244
MXV 2.074894
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Protagonist Therapeutics Reports Granting of Inducement Awards
Protagonist Therapeutics Reports Granting of Inducement Awards

Protagonist Therapeutics Reports Granting of Inducement Awards

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on January 2, 2025, it issued inducement awards to Newman Yeilding, M.D., upon his appointment to the role of Executive Vice President, Chief Scientific Officer, in accordance with the terms of his employment offer letter. Dr. Yeilding served in a consultant role as the Company's Chief Scientific Advisor from August 1, 2024 through January 1, 2025. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.

Text size:

Dr. Yeilding received options to purchase 38,520 shares and restricted stock units (RSUs) to acquire 31,779 shares of Protagonist Therapeutics common stock. The exercise price of the options is $38.98, which was the per-share closing price of Protagonist Therapeutics common stock on the Nasdaq Global Market on January 2, 2025. The shares subject to the option vest over a four-year period, with 25 percent of the shares subject to the option vesting on the first anniversary of Dr. Yeilding's date of hire and the remainder vesting in equal monthly installments over three years thereafter. One-fourth of the shares underlying the RSUs will vest annually over a four-year period. The awards were approved by the compensation committee of the Company's board of directors and were granted as a material inducement to Dr. Yeilding's entering into employment with the Company in accordance with Nasdaq Marketplace Rule 5635(c)(4).

About Protagonist Therapeutics

Protagonist Therapeutics is a late-stage development biopharmaceutical company focused on peptide therapeutics. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA potentially in 2025. Icotrokinra (JNJ-2113, formerly PN-235), licensed to Johnson & Johnson, is the first targeted oral peptide designed to selectively block the IL-23 receptor. Icotrokinra has successfully completed two Phase 3 psoriasis (PsO) studies (ICONIC-LEAD and ICONIC-TOTAL) and is currently in three additional Phase 3 PsO studies (ICONIC-ADVANCE 1, ICONIC-ADVANCE 2, and a Postular/Erythrodermic PSO study) and a Phase 2b ulcerative colitis study (ANTHEM-UC). Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera. Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered into in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage oral drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, oral anti-obesity peptides, and an oral hepcidin mimetic/ferroportin blocker.

More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at www.protagonist-inc.com.

Contact Information

Corey Davis Ph.D.
Investor Relations Contact - LifeSci Advisors
[email protected]
+1 212 915 2577

Virginia Amann
Media Relations Contact - ENTENTE Network of Companies
[email protected]
+1 833 500 0061 ext 1

SOURCE: Protagonist Therapeutics

D.Johnson--TFWP